Tune Therapeutics
Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network. The company is developing solutions for challenging diseases and building capacity to transform human health and medicine. Their proprietary platform, TEMPO, enables precise control over gene activity without altering DNA, expanding the scope of genetic medicine to address common, chronic, and age-related diseases. Their mission is to bring gene, cell, and regenerative therapies into a new era of human medicine to improve healthspan globally.
Industries
Nr. of Employees
medium (51-250)
Products
Epigenome editing platform for tunable gene regulation
A modular platform for precise activation or repression of gene expression via targeted epigenomic control without introducing genomic DNA breaks; designed for multiplex targeting across gene networks and cell types.
Epigenetic silencing therapeutic candidate for chronic Hepatitis B (TUNE-401)
Investigational therapeutic candidate that uses liver-targeted LNP delivery of RNA encoding an epi-silencing effector to epigenetically repress viral transcription from both integrated viral DNA and cccDNA in hepatocytes without altering host genomic sequence.
Epigenome editing platform for tunable gene regulation
A modular platform for precise activation or repression of gene expression via targeted epigenomic control without introducing genomic DNA breaks; designed for multiplex targeting across gene networks and cell types.
Epigenetic silencing therapeutic candidate for chronic Hepatitis B (TUNE-401)
Investigational therapeutic candidate that uses liver-targeted LNP delivery of RNA encoding an epi-silencing effector to epigenetically repress viral transcription from both integrated viral DNA and cccDNA in hepatocytes without altering host genomic sequence.
Services
Research collaborations and partnerships
Collaborative research and strategic partnerships to co-develop epigenome-editing programs, share preclinical data, and advance translational studies.
Clinical and investigator partnerships for early-phase trials
Partnerships with clinical investigators and trial sites to design and execute early-phase clinical studies and site-led trials.
Research collaborations and partnerships
Collaborative research and strategic partnerships to co-develop epigenome-editing programs, share preclinical data, and advance translational studies.
Clinical and investigator partnerships for early-phase trials
Partnerships with clinical investigators and trial sites to design and execute early-phase clinical studies and site-led trials.
Expertise Areas
- Epigenome editing and targeted epigenetic regulation
- RNA delivery and lipid nanoparticle formulation for liver targeting
- Preclinical translational studies including non-human primate and humanized mouse models
- Ex vivo cell therapy engineering using multiplex epigenome modulation
Key Technologies
- Epigenome editing
- Programmable DNA-binding epigenetic silencers
- Lipid nanoparticle (LNP) RNA delivery
- mRNA-encoded effector expression